# Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

> **NCT03483012** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Stereotactic radiosurgery (SRS)

## Key facts

- **NCT ID:** NCT03483012
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2019-11-21
- **Final completion:** 2025-11-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03483012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03483012, "Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03483012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*